Clinical trial
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With…
NCT00086879 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00086879 |
|---|---|
| Title | Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme |
| Official title | Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | carmustine, erlotinib hydrochloride, temozolomide |
| Enrollment | 110 |
| Start date | May 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2011 |
| First posted | Jul 12, 2004 |
| Last update posted | Jul 27, 2017 |
| Countries | Belgium, France, Italy, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: